



ASX Announcement

17 September 2021

Restricted securities to be released from escrow

Notice under Listing Rule 3.10A

MELBOURNE, AUSTRALIA (17 September 2021): Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing pezadeftide (formerly HXP124), as a potential new prescription topical treatment for onychomycosis, advises that 3,559,437 fully paid ordinary shares will be released from escrow on 25 September 2021 in accordance with ASX Listing Rule 3.10A. An application for quotation of these securities will be made following their release.

The release of these shares does not change the issued capital of the Company

This announcement is authorised for release to ASX by Michael Aldridge, Chief Executive Officer and Managing Director.

Enquiries:

Dr Nicole van der Weerden

Chief Operating Officer

n.vanderweerden@hexima.com.au

About Hexima

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit www.hexima.com.au. You can also find us on [Twitter](#) and [LinkedIn](#).